Adiponectin versus angiotensin II: Key pathological role of their misbalance

Kidney International

Volumn 70, Issue 10, 2006, Pages 1678-1679

  Suzuki, H ^a   Eguchi, S ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; OLMESARTAN;

DISEASE ASSOCIATION; HYPOADIPONECTINEMIA; METABOLIC DISORDER; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW;

EID: 33750598900     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001936     Document Type: Note

References (14)

1. Kadowaki T, Yamauchi T, Kubota N et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-1792.
2. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 29-33.
3. Furuhashi M, Ura N, Higashiura K et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81.
4. Koh KK, Quon MJ, Han SH et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687-3692.
5. Hattori Y, Akimoto K, Gross SS et al. Angiotensin-II-induced oxidative stress elicits hypoadiponectinaemia in rats. Diabetologia 2005; 48: 1066-1074.
6. Kurata A, Nishizawa H, Kihara S et al. Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006; 70: 1717-1724.
7. Furukawa S, Fujita T, Shimabukuro M et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-1761.
8. Kintscher U, Unger T. Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers. Acta Diabetol 2005; 42 (Suppl 1): S26-S32.
9. Chen H, Montagnani M, Funahashi T et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278: 45021-45026.
10. Suzuki H, Motley ED, Frank GD et al. Recent progress in signal transduction research of the angiotensin II type-1 receptor: protein kinases, vascular dysfunction and structural requirement. Curr Med Chem Cardiovasc Hematol Agents 2005; 3: 305-322.
11. Arita Y, Kihara S, Ouchi N et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002; 105: 2893-2898.
12. Ohtsu H, Suzuki H, Nakashima H et al. Angiotensin II signal transduction through small GTP-binding proteins: mechanism and significance in vascular smooth muscle cells. Hypertension 2006; 48: 534-540.
13. Nagata D, Takeda R, Sata M et al. AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation 2004; 110: 444-451.
14. Yamauchi T, Kamon J, Waki H et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003; 278: 2461-2468.